Navigation Links
Lilly to Expand Indianapolis Insulin Manufacturing Operations
Date:11/1/2012

INDIANAPOLIS, Nov. 1, 2012 /PRNewswire/ -- Local and state government officials joined representatives from Eli Lilly and Company (NYSE: LLY) today to announce a $140 million expansion to the company's Indianapolis insulin manufacturing operations.  The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the U.S., represents one of the most significant investments in Lilly's U.S.-based manufacturing operations in the past decade.

Construction will begin immediately with completion expected in March 2014. During this period, construction trade staffing will average 250, with peak employment at approximately 350 workers at the site. Once operational in 2015, more than 100 full-time, highly skilled, specialized technicians, scientists, and engineers will be needed to manage the operations.  

Diabetes care is a major segment of Lilly's pharmaceutical business with projections from health care experts – including the Centers for Disease Control and Prevention – indicating that as many as one in three U.S. adults could have diabetes by 2050.  The rise in prevalence of the disease is due, in part, to an aging population more likely to develop type 2 diabetes, increases in minority populations that are at high risk for type 2 diabetes, and people with diabetes living longer.  Diabetes afflicted 366 million people worldwide last year, according to the International Diabetes Federation.

John C. Lechleiter, Ph.D., Lilly's chairman, president, and chief executive officer, said that Lilly's commitment to meeting the long-term needs of people with diabetes in the U.S., as well as its role as a biomedical leader in Indiana, drove the company's decision to build this state-of-the-art manufacturing facility in Indianapolis. 

"Lilly is committed to providing a full range of innovative treatment options for people with diabetes," said Lechleiter.  "The need in our country is great – and it is growing.  This investment will help us to better meet that need while expanding our advanced manufacturing footprint in our home state – helping to strengthen Indiana's bioscience industry."

Lechleiter said the new facility will manufacture insulin cartridges for people with diabetes. It will be a first-of-its-kind facility for Lilly in the U.S.

Lilly's reorganization of its diabetes operations almost three years ago has provided greater focus on its innovation-based product portfolio and pipeline of potential new medicines.  Today, the company has 10 potential new diabetes medicines in various stages of clinical development including oral medications, insulins, and a once-a-week treatment to meet the needs of people with diabetes.      

Lilly's $140 million expansion is one of the largest economic development investments in both the city and state in 2012.

"Lilly is the premier pharmaceutical company in the world and their commitment to research keeps them ahead of the medical curve," said Lt. Governor Becky Skillman. "This expansion is just further proof that Indiana is a fiscally strong state, and we thank Lilly for their confidence in our state and our people."

"Lilly's expansion brings new jobs and investment of new capital to our local economy, demonstrating the company's confidence in doing business in Indianapolis and strengthening our advanced manufacturing and bioscience industries," said Indianapolis Mayor Greg Ballard. "We are pleased to see this industry leader that calls Indianapolis home continuing along its growth path, which is good for our community and the Central Indiana region as a whole."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
2. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
3. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
4. Lilly Announces Results From Lung Cancer Study
5. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
6. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
7. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
8. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
9. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
10. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
11. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses ... with the help of a weight loss surgery. The woman, declaring “I will not hate ... been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while it ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
Breaking Medicine News(10 mins):